Avacta says AVA6103 drug candidate achieves proof of mechanism in Phase 1 trial

By Reuters News

- Avacta Group PLC AVCT.L:

  • AVACTA ACHIEVES CLINICAL PROOF OF MECHANISM FOR THE NEXT GENERATION OF PRE|CISION® MEDICINES WITH AVA6103 (FAP-EXD) IN THE PHASE 1 FOCUS-01 TRIAL

  • AVACTA THERAPEUTICS - AVA6103 DEMONSTRATES CLEAN SAFETY PROFILE AT DOSE LEVEL 50% ABOVE MTD OF CONVENTIONAL EXATECAN

  • AVACTA THERAPEUTICS - FIRST EFFICACY DATA FROM FOCUS-01 TRIAL WITH AVA6103 EXPECTED IN H1 2027

Further company coverage: AVCT.L

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk